Renal connective tissue growth factor correlates with glomerular basement membrane thickness and prospective albuminuria in a non-human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy

Journal of Diabetes and its Complications

Volumn 22, Issue 4, 2008, Pages 284-294

  Thomson, Sally E ^a,b   McLennan, Susan V ^a,c   Kirwan, Paul D ^d   Heffernan, Scott J ^b   Hennessy, Annemarie ^a,b   Yue, Dennis K ^a,c   Twigg, Stephen M ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Renal Medicine ^*  (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Albuminuria; Connective tissue growth factor; CTGF; Diabetes; Glomerular basement membrane; Nephropathy; TIMP 1

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; HEMOGLOBIN A1C; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; ELECTRON MICROSCOPY; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FIBROSIS; MALE; MESANGIUM; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; URINALYSIS;

ALBUMINURIA; ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLOMERULAR BASEMENT MEMBRANE; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PAPIO HAMADRYAS; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 45849122111     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.07.001     Document Type: Article

References (46)

1. Adler S.G., Kang S.W., Feld S., Cha D.R., Barba L., Striker L., Striker G., Riser B.L., LaPage J., and Nast C.C. Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria?. American Journal of Kidney Diseases 40 (2002) 184-188
2. Andersen S., van Nieuwenhoven F.A., Tarnow L., Rossing P., Rossing K., Wieten L., Goldschmeding R., and Parving H.H. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney International 67 (2005) 2325-2329
3. Basgen J.M., Rich S.S., Mauer S.M., and Steffes M.W. Measuring the volume density of the glomerular mesangium. Nephron 50 (1988) 182-186
4. Birn H., and Christensen E.I. Renal albumin absorption in physiology and pathology. Kidney International 69 (2006) 440-449
5. Birrell A.M., Heffernan S.J., Kirwan P., McLennan S., Gillin A.G., and Yue D.K. The effects of aminoguanidine on renal changes in a baboon model of Type 1 diabetes. Journal of Diabetes and its Complications 16 (2002) 301-309
6. Brito P.L., Fioretto P., Drummond K., Kim Y., Steffes M.W., Basgen J.M., Sisson-Ross S., and Mauer M. Proximal tubular basement membrane width in insulin-dependent diabetes mellitus. Kidney International 53 (1998) 754-761
7. Cooper M.E., Gilbert R.E., and Epstein M. Pathophysiology of diabetic nephropathy. Metabolism 47 (1998) 3-6
8. Denton C.P., and Abraham D.J. Transforming growth factor-beta and connective tissue growth factor: Key cytokines in scleroderma pathogenesis. Current Opinion in Rheumatology 13 (2001) 505-511
9. Finckenberg P., Inkinen K., Ahonen J., Merasto S., Louhelainen M., Vapaatalo H., Muller D., Ganten D., Luft F., and Mervaala E. Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. American Journal of Pathology 163 (2003) 355-366
10. Frazier K., Williams S., Kothapalli D., Klapper H., and Grotendorst G.R. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. Journal of Investigative Dermatology 107 (1996) 404-411
11. Gilbert R.E., and Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?. Kidney International 56 (1999) 1627-1637
12. Gupta S., Clarkson M.R., Duggan J., and Brady H.R. Connective tissue growth factor: Potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney International 58 (2000) 1389-1399
13. Heffernan S., James V., Zilkens R., Kirwan P., Birrell A., McLennan S., Hennessy A., Gillin A., Horvath J., Tiller D., Yue D., and Turtle J. Changes of extracellular matrix in a baboon (Papio hamadryas) model of insulin dependent diabetes: Studies using electron microscopy and X-ray diffraction techniques. Diabetes Research and Clinical Practice 34 (1996) 65-72
14. Heffernan S., Phippard A., Sinclair A., McLennan S., Hennessy A., Gillin A., Horvath J., Tiller D., Yue D., and Turtle J. A baboon (Papio hamadryas) model of insulin-dependent diabetes. Journal of Medical Primatology 24 (1995) 29-34
15. Hirose K., Osterby R., Nozawa M., and Gundersen H.J. Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney International 21 (1982) 689-695
16. Ito Y., Aten J., Bende R.J., Oemar B.S., Rabelink T.J., Weening J.J., and Goldschmeding R. Expression of connective tissue growth factor in human renal fibrosis. Kidney International 53 (1998) 853-861
17. Ito Y., Goldschmeding R., Bende R., Claessen N., Chand M., Kleij L., Rabelink T., Weening J., and Aten J. Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. Journal of the American Society of Nephrology 12 (2001) 472-484
18. Lehmann R., and Schleicher E.D. Molecular mechanism of diabetic nephropathy. Clinica Chimica Acta 297 (2000) 135-144
19. Liu B.C., Chen L., Sun J., Huang H.Q., Ma K.L., Liu H., Liu D.G., and Zhang X.L. Connective tissue growth factor-mediated angiotensin II-induced hypertrophy of proximal tubular cells. Nephron. Experimental Nephrology 103 (2006) e16-e26
20. Marquez B., Zouvani I., Karagrigoriou A., Anastasiades E., Pierides A., and Kyriacou K. A simplified method for measuring the thickness of glomerular basement membranes. Ultrastructural Pathology 27 (2003) 409-416
21. McLennan S.V., Fisher E.J., Yue D.K., and Turtle J.R. High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 43 (1994) 1041-1045
22. McLennan S.V., Kelly D.J., Cox A.J., Cao Z., Lyons J.G., Yue D.K., and Gilbert R.E. Decreased matrix degradation in diabetic nephropathy: Effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 45 (2002) 268-275
23. McLennan S.V., Wang X.Y., Moreno V., Yue D.K., and Twigg S.M. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: Implications for diabetic nephropathy. Endocrinology 145 (2004) 5646-5655
24. Murphy M., Godson C., Cannon S., Kato S., Mackenzie H.S., Martin F., and Brady H.R. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. Journal of Biological Chemistry 274 (1999) 5830-5834
25. Nguyen T.Q., Tarnow L., Andersen S., Hovind P., Parving H.H., Goldschmeding R., and van Nieuwenhoven F.A. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 29 (2006) 83-88
26. Osterby R. Early phases in the development of diabetic glomerulopathy. Acta medica Scandinavica. Supplementum 574 (1974) 3-82
27. Osterby R., Gundersen H.J., Horlyck A., Kroustrup J.P., Nyberg G., and Westberg G. Diabetic glomerulopathy. Structural characteristics of the early and advanced stages. Diabetes 32 Suppl. 2 (1983) 79-82
28. Reckelhoff J.F., Tygart V.L., Mitias M.M., and Walcott J.L. STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloprotease in rats. Diabetes 42 (1993) 1425-1432
29. Riser B.L., Cortes P., DeNichilo M., Deshmukh P.V., Chahal P.S., Mohammed A.K., Yee J., and Kahkonen D. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: Preliminary report. Kidney International 64 (2003) 451-458
30. Riser B.L., Denichilo M., Cortes P., Baker C., Grondin J.M., Yee J., and Narins R.G. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. Journal of the American Society of Nephrology 11 (2000) 25-38
31. Roestenberg P., van Nieuwenhoven F.A., Wieten L., Boer P., Diekman T., Tiller A.M., Wiersinga W.M., Oliver N., Usinger W., Weitz S., Schlingemann R.O., and Goldschmeding R. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 27 (2004) 1164-1170
32. Ruperez M., Lorenzo O., Blanco-Colio L.M., Esteban V., Egido J., and Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 108 (2003) 1499-1505
33. Shankland S.J., Ly H., Thai K., and Scholey J.W. Glomerular expression of tissue inhibitor of metalloproteinase (TIMP-1) in normal and diabetic rats. Journal of the American Society of Nephrology 7 (1996) 97-104
34. Steffen C.L., Ball-Mirth D.K., Harding P.A., Bhattacharyya N., Pillai S., and Brigstock D.R. Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro. Growth Factors 15 (1998) 199-213
35. Steffes M.W., Osterby R., Chavers B., and Mauer S.M. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38 (1989) 1077-1081
36. Tikellis C., Cooper M.E., Twigg S.M., Burns W.C., and Tolcos M. Connective tissue growth factor is up-regulated in the diabetic retina: Amelioration by angiotensin-converting enzyme inhibition. Endocrinology 145 (2004) 860-866
37. Twigg S.M., Cao Z., McLennan S.V., Burns W.C., Brammar G., Forbes J.M., and Cooper M.E. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143 (2002) 4907-4915
38. Twigg S.M., Chen M.M., Joly A.H., Chakrapani S.D., Tsubaki J., Kim H.S., Oh Y., and Rosenfeld R.G. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: A potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142 (2001) 1760-1769
39. Twigg S.M., and Cooper M.E. The time has come to target connective tissue growth factor in diabetic complications. Diabetologia 47 (2004) 965-968
40. Twigg S.M., Joly A.H., Chen M.M., Tsubaki J., Kim H.S., Hwa V., Oh Y., and Rosenfeld R.G. Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143 (2002) 1260-1269
41. van Nieuwenhoven F.A., Jensen L.J., Flyvbjerg A., and Goldschmeding R. Imbalance of growth factor signalling in diabetic kidney disease: Is connective tissue growth factor (CTGF, CCN2) the perfect intervention point?. Nephrology Dialysis Transplantation 20 (2005) 6-10
42. Wada J., Makino H., and Kanwar Y.S. Gene expression and identification of gene therapy targets in diabetic nephropathy. Kidney International 61 Suppl. 1 (2002) 73-78
43. Wang S., Denichilo M., Brubaker C., and Hirschberg R. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney International 60 (2001) 96-105
44. Yokoi H., Mukoyama M., Nagae T., Mori K., Suganami T., Sawai K., Yoshioka T., Koshikawa M., Nishida T., Takigawa M., Sugawara A., and Nakao K. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. Journal of the American Society of Nephrology 15 (2004) 1430-1440
45. Yokoi H., Mukoyama M., Sugawara A., Mori K., Nagae T., Makino H., Suganami T., Yahata K., Fujinaga Y., Tanaka I., and Nakao K. Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. American Journal of Physiology. Renal Physiology 282 (2002) F933-F942
46. Yokoi H., Sugawara A., Mukoyama M., Mori K., Makino H., Suganami T., Nagae T., Yahata K., Fujinaga Y., Tanaka I., and Nakao K. Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: A potential target for preventing renal fibrosis. American Journal of Kidney Diseases 38 (2001) S134-S138